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Often  dysfunctional,  difﬁcult  to  assess  with  ultrasound  techniques,  with  fewer  out-
come  data  and  more  contradictory  results  than  the  other  valve  diseases,  the  tricuspid
valve  (TV)  is  the  most  challenging  valve  for  the  clinician  [1—3];  it  is  often  called  the
‘‘forgotten  valve’’.  While  TV  stenosis  is  rather  uncommon,  TV  regurgitation  (TR)  is  fre-
quent,  but  still  poorly  deﬁned.  Trivial  TR  is  frequently  detected  by  echocardiography  in
normal  subjects.  Pathological  TR  is  more  often  secondary,  rather  than  resulting  from
a  primary  valve  lesion  (intrinsic  morphopathological  changes  of  the  TV  complex)  [4].
Causes  of  primary  TR  are  infective  endocarditis,  rheumatic  heart  disease,  carcinoid  syn-
drome,  myxomatous  disease,  endomyocardial  ﬁbrosis,  Ebstein’s  disease,  thoracic  trauma,
pacemaker  leads/catheters  interfering  with  leaﬂet  coaptation  and  drug-induced  valve  dis-
ease.  Secondary  TR  is  mainly  caused  by  dilation  of  the  tricuspid  annulus  and  tethering
of  the  TV  leaﬂets  secondary  to  right  ventricular  dysfunction  caused  by  chronic  pres-
sure  (i.e.  left-sided  heart  disease  or  pulmonary  hypertension)  or  volume  overload  (i.e.Régurgitation  ;
Traitement  ;
Approche  percutanée
atrial  septal  defects  or  intrinsic  disease  of  the  right  ventricle  [RV])  [5].  Some  authors
distinguish  a  third  entity,  at  the  border  between  primary  and  secondary  TR,  so-called
‘‘idiopathic’’  TR,  in  which  annular  enlargement  (possibly  of  degenerative  aetiology,  but
with  normal  leaﬂet  morphology)  plays  the  central  role  in  TR  genesis  [6].  ‘‘Idiopathic’’
Abbreviations: 3D, three-dimensional; CMR, cardiac magnetic resonance; CT, computed tomography; RV, right ventricle/ventricular;
TR, tricuspid valve regurgitation; TV, tricuspid valve.
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inferior  vena  cava  in  those  patients  with  refractory  periph- 
R  is  more  often  observed  in  elderly  patients  with  atrial
brillation,  but  the  diagnosis  can  only  be  made  after  exclu-
ion  of  other  potential  causes  of  TR.  Distinction  between
hese  entities  represents  the  ﬁrst  step  in  the  imaging  assess-
ent  of  TR,  as  elegantly  highlighted  in  the  current  issue  of
he  journal  by  Huttin  et  al.  [7].
Echocardiography  is  the  key  imaging  method  for  the  eval-
ation  of  TR.  In  fact,  the  management  of  patients  with  TR
argely  integrates  the  results  of  echocardiography;  it  pro-
ides  detailed  anatomical  and  functional  information,  and
lariﬁes  the  mechanisms  that  play  a  role  in  TR  [4].  Presence
f  vegetations,  leaﬂet  thickening  and  retraction  (carcinoid,
heumatic  and  drug-induced  valve  disease),  prolapsing/ﬂail
eaﬂets  (myxomatous  or  post-traumatic  disease)  or  dys-
lastic  TV  with  a  distance  between  the  tricuspid  septal
eaﬂet  insertion  point  to  anterior  mitral  leaﬂet  >  8  mm/m2
Ebstein’s  disease)  would  plead  for  primary  TR.  Secondary
R  is  conﬁrmed  by  measurement  of  the  tricuspid  annular
imensions,  TV  deformation,  RV  function  and  remodelling,
nd  systolic  pulmonary  artery  pressure.  Signiﬁcant  tricuspid
nnular  dilatation  is  deﬁned  by  a  diastolic  diameter  ≥  40  mm
r  ≥  21  mm/m2 (cut-off  derived  from  surgical  studies)  in
he  four-chamber  transthoracic  view.  Signiﬁcant  TV  tether-
ng,  based  on  postoperative  residual  TR  after  TV  repair  for
econdary  TR,  is  deﬁned  as  a  coaptation  distance  >  8  mm
distance  between  the  tricuspid  annular  plane  and  the
oint  of  coaptation  in  mid-systole  from  the  apical  four-
hamber  view),  a  tenting  area  >  1.63  cm2 and  a  tethering
istance  >  0.76  cm.  Similar  to  mitral  regurgitation,  mixed
orms  of  TR  may  be  encountered  in  advanced  stages  of  the
isease.  In  these  cases,  three-dimensional  (3D)  echocardi-
graphy  may  play  a  crucial  role  in  outlining  the  TR  aetiology
4].
Colour  Doppler  echocardiography  not  only  detects  the
resence  of  regurgitation,  but  also  permits  an  understand-
ng  of  the  mechanisms  of  regurgitation  (very  eccentric
ets  may  favour  primary  TR  while  central  jets  favour
econdary  TR)  and  quantiﬁcation  of  its  severity  and  reper-
ussions.  Practically,  the  evaluation  of  TR  requires  the  use  of
ifferent  echocardiographic  modalities  (M-mode,  Doppler,
wo-dimensional/3D  and  transoesophageal  echocardiogra-
hy),  should  integrate  multiple  variables  and  should  be
upported  by  clinical  data.  The  width  of  the  vena  con-
racta  seems  to  be  the  most  reliable  quantitative  index;
 vena  contracta  diameter  >  7  mm  is  a  good  marker  of
evere  TR.  The  proximal  ﬂow  convergence  method  has  been
oorly  validated,  but  retained  criteria  for  severe  TR  affect-
ng  patient  outcome  are  an  effective  regurgitant  oriﬁce
rea  >  40  mm2 and  a  regurgitant  volume  >  45  mL  [8].  In  their
eview,  Huttin  et  al.  emphasized  the  need  to  account  for
espiration-induced  changes  in  TR  severity,  and  the  neces-
ity  to  re-evaluate  the  patients  after  optimization  of  loading
onditions,  especially  when  isolated  TV  surgery  is  con-
emplated.  The  authors  also  outlined  the  complementary
sefulness  of  cardiac  computed  tomography  (CT)  and  car-
iac  magnetic  resonance  (CMR)  in  the  assessment  of  patients
ith  TR  [7].
Special  attention  was  also  given  to  the  relationshipetween  TR  and  RV  function.  The  authors  reiterated  that  the
V,  being  a  volume-pump,  tolerates  an  increase  in  volume
verload  rather  well.  Signiﬁcant  TR  may  thus  be  clinically
e
e
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ilent  for  a prolonged  period,  during  which  progressive  RV
ilatation  and  dysfunction  may  develop  [3].  This  has  led
o  the  general  principle  that  surgery  should  be  carried  out
arly  enough  to  avoid  irreversible  RV  dysfunction  [2,3].  How-
ver,  the  load  dependency  of  all  echocardiographic  and  CMR
erived  variables  of  RV  function,  and  the  fact  that  some  may
e  altered  even  in  the  absence  of  RV  contractile  dysfunction,
epresent  non-negligible  limitations  to  the  prediction  of  RV
unction  improvement  after  corrective  surgery  [7].
Eventually,  the  TR  patient  may  be  managed  with  diuret-
cs  for  symptoms,  and  only  considered  for  surgery  after
dvanced  RV  dysfunction,  even  when  liver  dysfunction  or
irrhosis  has  developed.  It  should  be  no  surprise,  therefore,
hat  results  from  the  Society  of  Thoracic  Surgeons  Database
ndicated  that  TV  surgery  is  the  most  high-risk  valve  oper-
tion  in  terms  of  morbidity  and  mortality  [9].  Although
itral  valve  surgery  has  evolved  over  the  past  few  decades
owards  progressively  earlier  intervention,  even  in  selected
symptomatic  patients,  no  such  evolution  has  occurred  in
V  surgery  as  yet  [2,3].  The  relative  paucity  of  articles  on
he  TV  compared  with  left-sided  valves  and  the  lack  of  ran-
omized  trials  have  all  contributed  to  intensify  this  problem.
ctually,  in  patients  scheduled  for  mitral  valve  surgery,  TR
s  far  from  uncommon.  Historically,  TR  secondary  to  mitral
alve  disease  was  thought  to  improve  after  mitral  valve
urgery;  this  led  to  a conservative  non-surgical  approach
o  TR.  However,  recent  studies  have  clearly  challenged  this
oncept,  showing  excess  cardiovascular  events  when  not
reated.  Therefore,  mitral  valve  surgery  alone  cannot  be
xpected  to  result  in  effective  TR  control  [10].
The  current  European  and  American  guidelines  for  the
anagement  of  valvular  heart  disease  suggest  that  TV
urgery  is  recommended  for  patients  with  severe  TR  under-
oing  left-sided  valve  surgery  (Class  I),  and  that  TV  surgery
an  be  valuable  for  patients  with  at  least  moderate  TR  with
ricuspid  annular  dilation  (Class  IIa)  [2,3]. Recurrence  of  TR
ong  after  TV  plasty  is  not  as  uncommon  (as  high  as  60%  at  5
ears),  and  surgery  may  be  needed  in  up  to  20%  of  patients
fter  10  years  [11]. In  these  patients,  as  reoperation  on  the
V  carries  a  very  high  surgical  risk,  percutaneous  approaches
ight  become  valuable  alternatives  in  the  near  future.
A  review  of  the  techniques  currently  available  and  a  com-
rehensive  description  of  several  cases  from  experience  at
ichat  Hospital  have  been  provided  in  the  current  issue
f  the  journal  by  Bouleti  et  al.  [12].  So  far,  transcatheter
nterventions  for  TV  disease  have  been  mainly  suggested
or  patients  with  a  degenerating  bioprosthesis,  with  mixed
esults  [13]. Indeed,  valve-in-valve  reimplantation  proce-
ures  are  subject  to  fewer  complications  than  valve-in-ring
rocedures,  in  which  signiﬁcant  paravalvular  regurgitation
s  common  in  incomplete  rigid  rings.  Valve-in-native  valve
mplantation  is  more  technically  challenging.  This  is  the
esult,  in  part,  of  the  absence  of  a  rigid  landing  zone  for
alve  deployment,  such  as  in  aortic  stenosis,  as  well  as  the
ariety  of  annular  dimensions  that  may  occur  in  severe  TR
14]. This  has  recently  led  to  some  experience  with  het-
rotopic  placement  of  transcatheter  aortic  valves  in  theral  signs  of  RV  failure  [15].  Although  short-term  results  are
ncouraging,  long-term  studies  are  needed.  Bicuspidization
echniques  to  treat  TR  are  also  explained  in  detail  by  the
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authors.  Other  newer  techniques,  such  as  the  FORMA  repair
system  (Edwards  Lifesciences,  Irvine,  CA,  USA)  and  the  Mil-
lipede  system  (Millipede,  LLC,  Ann  Arbor,  MI,  USA)  are  also
reported  as  means  to  extend  current  percutaneous  options
to  TR  reduction.  The  option  of  transjugular  use  of  the  Mitr-
aClip  system  (Abbott  Vascular  Inc.,  Santa  Clara,  CA,  USA)
to  attempt  leaﬂet  tethering  and  decrease  functional  TR  has
also  been  outlined,  although  such  an  approach  maybe  ques-
tionable  in  case  of  severe  tricuspid  annulus  dilatation  and
wide  malcoaptation  gaps.
Currently,  there  is  no  single  therapeutic  approach  for  the
percutaneous  treatment  of  TR,  although  an  increasing  num-
ber  of  patients  with  severe  TR  exist.  General  agreement
regarding  appropriate  patient  selection,  optimal  index  of
treatment  and  standardized  imaging  approach  (echocardi-
ography,  CMR,  CT)  is  necessary  for  these  patients.  Clinical
and  technical  challenges  associated  with  percutaneous  ther-
apies  of  TR  are  preventive  features,  and  represent  the  next
frontiers  that  clinicians  will  need  to  overcome.
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